Petros Pharmaceuticals announces transition from Nasdaq to OTC Markets

Written by Emily J. Thompson, Senior Investment Analyst

PTPI%

Updated: May 21 2025

0mins

Delisting from Nasdaq: Petros Pharmaceuticals has received a letter from Nasdaq indicating that its common stock will be suspended and delisted from the exchange starting May 22, 2025.
Transition to OTC Markets: Following the suspension, Petros' securities are expected to begin trading on the OTC Markets under the ticker "PTPI".

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Petros Pharmaceuticals announces transition from Nasdaq to OTC Markets

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

XRP Drops 40% from July Peak; Ripple's Products Face Adoption Challenges

Shiba Inu's Market Cap Drops 90%, Increasing Investment Risks

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch